Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.71 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | POLD1 | P28340 | 1/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199313 | 1.00 | POLG (0.71) | POLGALBP2RY2POLBPOLA1 | |
| SCHEMBL13199316 | 0.89 | POLG (0.57) | POLGP2RY2POLBPOLA1POLD1 | |
| SCHEMBL9856279 | 0.89 | POLG (0.57) | POLGP2RY2POLBPOLA1POLD1 | |
| SCHEMBL15810766 | 0.89 | POLG (0.56) | POLGP2RY2POLBPOLA1POLD1 | |
| SCHEMBL16807755 | 0.89 | POLG (0.56) | POLGP2RY2POLBPOLA1POLD1 | |
| SCHEMBL15810726 | 0.89 | POLG (0.56) | POLGP2RY2POLBPOLA1POLD1 | |
| SCHEMBL15810743 | 0.88 | POLG (0.55) | POLGP2RY2POLBPOLA1POLD1 | |
| SCHEMBL25492503 | 0.84 | POLG (0.70) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL8409011 | 0.84 | POLG (0.70) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL8409014 | 0.84 | POLG (0.70) | POLGP2RY2POLBP2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0517986-B1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | EUROP COMMUNITIES (LU) | 1997-09-10 | — | — | EP | claimed |
| EP-0517986-A1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-16 | — | — | EP | claimed |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2021-04-15 | — | — | US | disclosed |
| WO-2004013298-A2 | 2',3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVITRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2004-02-12 | — | — | WO | disclosed |
| US-5753221-A | CONTAINING TRIPHOSPHORYLATED NUCLEOSIDE ANALOG WHICH INHIBITS REVERSE TRANSCRIPTASE; VIRICIDES | COMMUNAUTE ECONOMIQUE EUROPEENE (LU) | 1998-05-19 | — | — | US | disclosed |
| EP-0517986-B1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | EUROP COMMUNITIES (LU) | 1997-09-10 | — | — | EP | disclosed |
| WO-1992022306-A1 | TRANSFORMED ERYTHROCYTES, PROCESS FOR PREPARING THE SAME, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-23 | — | — | WO | disclosed |
| EP-0517986-A1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | POLG 506/4885ALB 2964/4885P2RY2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.